Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional Post-Authorisation Safety Study (PASS) in Male Haemophilia B Patients Receiving Nonacog Beta Pegol (N9-GP) Prophylaxis Treatment

NCT03745924 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03745924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03745924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional Post-Authorisation Safety Study (PASS) in Male Haemophilia B Patients Receiving Nonacog Beta Pegol (N9-GP) Prophylaxis Treatment
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Enrolling by invitation
Start date
April 1, 2019
Completion date
December 15, 2027
Enrollment
60 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia b